Cboe CA - Delayed Quote CAD

AbbVie Inc. (ABBV.NE)

28.47

+0.72

+(2.59%)

At close: May 2 at 2:31:06 PM EDT

Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash?

President Trump recently warned big drugmakers that a pharmaceutical "tariff wall" is coming. Investors often view Pharmaceutical stocks as safe havens during periods of market turbulence. Indeed, shares of the three biggest pharmaceutical companies based on market cap -- AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), and Johnson & Johnson (NYSE: JNJ) -- have all delivered solid gains so far this year, while the major market indexes have fallen.

Motley Fool 6 hours ago

JNJ

ABBV

LLY
AbbVie Stock: Using A Long-Term Leap Ratio Spread On This Pharma Giant

Positive post-earnings and a general upward draft of price action in the markets make for a strong argument for a bullish setup on AbbVie.

Investor's Business Daily 2 days ago

ABBV
Transforming HR Leadership: Inside The Darla Moore School’s Standout MHR Program

CHRO of AbbVie Tim Richmond at the SC Moore School. Courtesy photo At the University of South Carolina’s Darla Moore School of Business, the Master of Human Resources (MHR) program is not just thriving—it’s ... The post Transforming HR Leadership: Inside The Darla Moore School’s Standout MHR Program appeared first on Poets&Quants.

Poets & Quants 2 days ago

ABBV
BOTOX® Cosmetic (onabotulinumtoxinA) Continues its Mission of Empowering Entrepreneurs Through "The Confidence Project"

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced BOTOX® Cosmetic's continued commitment to closing the Confidence Gap with the introduction of The Confidence Project: Empowering Women Entrepreneurs. The one & only BOTOX® Cosmetic invites business owners to apply for this year's program starting today through May 9, 2025, at 11:59pm PT.

PR Newswire 2 days ago

ABBV
High Growth Tech Stocks In The US Market April 2025

The United States market has experienced a notable upswing, climbing 5.2% in the last week and showing a 9.9% increase over the past year, with earnings projected to grow by 14% annually in the coming years. In this dynamic environment, identifying high growth tech stocks involves focusing on companies that demonstrate robust innovation and adaptability to capitalize on these favorable market conditions.

Simply Wall St. 4 days ago

ABBV

CGNX

CVLT
FDA approves AbbVie’s upadacitinib for giant cell arteritis

The approval of the therapy is backed by the outcomes from the randomised Phase III SELECT-GCA trial.

Pharmaceutical Technology 4 days ago

ABBV
Moderna (MRNA) Reports Earnings Tomorrow: What To Expect

Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results tomorrow before market hours. Here’s what you need to know.

StockStory 4 days ago

MRNA

ABBV
Amgen (AMGN) Reports Earnings Tomorrow: What To Expect

Biotech company Amgen (NASDAQ:AMGN) will be reporting earnings tomorrow afternoon. Here’s what to expect.

StockStory 4 days ago

AMGN

ABBV
Biogen Earnings: What To Look For From BIIB

Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow before the bell. Here’s what you need to know.

StockStory 4 days ago

BIIB

ABBV
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q1 Earnings

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting earnings tomorrow after the bell. Here’s what to look for.

StockStory 4 days ago

BMRN

ABBV
AbbVie (NYSE:ABBV) Receives FDA Approval For RINVOQ In Treating Giant Cell Arteritis

AbbVie (NYSE:ABBV) recently secured FDA approval for RINVOQ to treat giant cell arteritis, which alongside a biologics license application for TrenibotE, underscored the company's focus on innovation. Despite a 13% rise in its share price over the past week, AbbVie's gains were in line with the broader market's 7% climb, suggesting these product developments and positive sales growth added weight to the general upward momentum. Meanwhile, the broader market's reaction to strong earnings...

Simply Wall St. 4 days ago

ABBV
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

Zacks 5 days ago

ABBV
Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Zacks 5 days ago

ABBV
RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)

AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA).1 This comes after the European Commission recently granted marketing authorization of RINVOQ for the treatment of GCA in adult patients.

PR Newswire 5 days ago

ABBV
United Therapeutics (UTHR) To Report Earnings Tomorrow: Here Is What To Expect

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow morning. Here’s what to look for.

StockStory 5 days ago

UTHR

ABBV
Why AbbVie Stock Trounced the Market Today

Of the two notes, arguably the more impactful was the one BMO Capital's Evan David Seigerman published before market open. The analyst continues to be positive on AbbVie, as he maintained his outperform (buy, in other words) recommendation on the stock and $215 per-share price target. Not surprisingly, according to reports, Seigerman focused on AbbVie's first-quarter earnings release that was published on Friday.

Motley Fool 5 days ago

ABBV

^GSPC
S&P 500 Gains and Losses Today: AbbVie Stock Advances After Beat-and-Raise Earnings Report

The S&P 500 edged 0.1% higher on Monday, April 28, eking out a fifth straight winning session to kick off a week of key earnings reports and economic data releases.

Investopedia 5 days ago

ABBV

^GSPC

NVDA
AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts

First-quarter adjusted earnings per share were $2.46 on sales of $13.3 billion, above analysts’ expectations.

Barrons.com 6 days ago

ABBV

^GSPC
ALX Oncology’s CD47-blocker and Keytruda combo fails in two Phase II trials

Despite the failures, ALX Oncology remains hopeful about evorpacept and is focusing on combination trials with other anti-cancer antibodies.

Clinical Trials Arena 6 days ago

ALXO

ABBV
3 Dividend Stocks to Buy and Hold for the Next Decade

Three Motley Fool contributors believe they've identified fantastic dividend stocks to buy and hold for the next decade. Here's why they chose Abbott Laboratories (NYSE: ABT), AbbVie (NYSE: ABBV), and Pfizer (NYSE: PFE).

Motley Fool 6 days ago

ABBV

PFE

ABT

Performance Overview

Return	ABBV.NE	S&P 500 (^GSPC)
YTD	+13.01%	-3.31%
1-Year	+24.84%	+12.29%
3-Year	+19.47%	+36.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AbbVie Inc. (ABBV.NE)

Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash?

AbbVie Stock: Using A Long-Term Leap Ratio Spread On This Pharma Giant

Transforming HR Leadership: Inside The Darla Moore School’s Standout MHR Program

BOTOX® Cosmetic (onabotulinumtoxinA) Continues its Mission of Empowering Entrepreneurs Through "The Confidence Project"

High Growth Tech Stocks In The US Market April 2025

FDA approves AbbVie’s upadacitinib for giant cell arteritis

Moderna (MRNA) Reports Earnings Tomorrow: What To Expect

Amgen (AMGN) Reports Earnings Tomorrow: What To Expect

Biogen Earnings: What To Look For From BIIB

What To Expect From BioMarin Pharmaceutical’s (BMRN) Q1 Earnings

AbbVie (NYSE:ABBV) Receives FDA Approval For RINVOQ In Treating Giant Cell Arteritis

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)

United Therapeutics (UTHR) To Report Earnings Tomorrow: Here Is What To Expect

Why AbbVie Stock Trounced the Market Today

S&P 500 Gains and Losses Today: AbbVie Stock Advances After Beat-and-Raise Earnings Report

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts

ALX Oncology’s CD47-blocker and Keytruda combo fails in two Phase II trials

3 Dividend Stocks to Buy and Hold for the Next Decade

Performance Overview